Bordetella bronchiseptica Bacteriophage Bor-BRP-1 for Targeted Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating Bordetella bronchiseptica infections, such as antibiotics, face challenges due to increasing antibiotic resistance and environmental concerns, necessitating the development of alternative, specifically targeted therapies.
Innovation Solution
Isolation and use of a Podoviridae bacteriophage, Bor-BRP-1, which specifically infects and kills Bordetella bronchiseptica, formulated into a composition for prevention and treatment, including as a disinfectant and feed additive.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used for treatment, then bacterial infections are eliminated, but antibiotic resistance increases and normal flora is disturbed
Solution Approach 1:
The patent applies segmentation by using a specific bacteriophage (Podoviridae family) that targets only Bordetella bronchiseptica bacteria. This segmented approach divides the broad-spectrum antibiotic effect into a narrow-spectrum phage therapy, eliminating the target pathogen while preserving commensal bacteria in the animal's microbiome.
Solution Approach 2:
The bacteriophage acts as an intermediary agent between the treatment goal (killing B. bronchiseptica) and the animal host. The phage selectively infects and lyses the pathogenic bacteria through its specific receptor binding, serving as a mediator that eliminates the harmful bacteria without affecting the host's normal flora or inducing resistance.
2Object-generated harmful factors
If bacteriophages are used for treatment, then specificity against target bacteria is achieved, but treatment effectiveness may be limited to specific bacterial strains
Solution Approach 1:
The patent applies local quality by engineering or selecting a bacteriophage with specific local properties (surface proteins, tail fibers) that recognize and bind to unique receptors on Bordetella bronchiseptica cells. This localized specificity at the molecular interaction level enables the phage to distinguish the target pathogen from commensal bacteria, achieving selective therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacteriophage composition effectively inhibits and treats Bordetella bronchiseptica infections with high specificity, minimizing impact on commensal bacteria and environmental harm, offering a sustainable alternative to conventional antibiotics.
Implementation Method 1
Once a bacteriophage infects bacteria, the bacteriophage is proliferated in the inside of the bacterial cell. After proliferation, the progeny of the bacteriophage destroys the bacterial cell wall and escapes from bacteria as the host, suggesting that the bacteriophage has the ability to kill bacteria.
Data Source
AI summary
The present invention relates to a Podoviridae bacteriophage Bor-BRP-1 (accession no. KCTC 12705BP) isolated from nature, which has an ability to specifically kill Bordetella bronchiseptica bacteria and has a genome represented by SEQ ID NO: 1; and a method for preventing and treating infection with Bordetella bronchiseptica bacteria using a composition comprising the same as an active ingredient.